170 related articles for article (PubMed ID: 23357846)
1. Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid.
Cha YJ; Lee YJ
Int J Clin Pharmacol Ther; 2013 Apr; 51(4):274-82. PubMed ID: 23357846
[TBL] [Abstract][Full Text] [Related]
2. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
[TBL] [Abstract][Full Text] [Related]
3. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.
Boonen S; Sellmeyer DE; Lippuner K; Orlov-Morozov A; Abrams K; Mesenbrink P; Eriksen EF; Miller PD
Kidney Int; 2008 Sep; 74(5):641-8. PubMed ID: 18509324
[TBL] [Abstract][Full Text] [Related]
4. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
Weide R; Koppler H; Antras L; Smith M; Chang MP; Green J; Wintfeld N; Neary MP; Duh MS
J Cancer Res Ther; 2010; 6(1):31-5. PubMed ID: 20479544
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
[TBL] [Abstract][Full Text] [Related]
6. Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model.
McDermott RS; Kloth DD; Wang H; Hudes GR; Langer CJ
J Support Oncol; 2006; 4(10):524-9. PubMed ID: 17136870
[TBL] [Abstract][Full Text] [Related]
7. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
Oh WK; Proctor K; Nakabayashi M; Evan C; Tormey LK; Daskivich T; Antràs L; Smith M; Neary MP; Duh MS
Cancer; 2007 Mar; 109(6):1090-6. PubMed ID: 17311345
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid treatment at home: safety data from an observational prospective trial.
Tassinari D; Poggi B; Nicoletti S; Fantini M; Tamburini E; Possenti C; Sartori S
J Palliat Med; 2007 Apr; 10(2):352-8. PubMed ID: 17472506
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid in metastatic bone disease: an audit based discussion.
Akbar RA; Gosh SK; Khalil S; ul Haq SM
J Ayub Med Coll Abbottabad; 2010; 22(3):5-7. PubMed ID: 22338405
[TBL] [Abstract][Full Text] [Related]
10. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Diel IJ; Weide R; Köppler H; Antràs L; Smith M; Green J; Wintfeld N; Neary M; Duh MS
Support Care Cancer; 2009 Jun; 17(6):719-25. PubMed ID: 19089462
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid.
Chennuru S; Koduri J; Baumann MA
Intern Med J; 2008 Aug; 38(8):635-7. PubMed ID: 18284458
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
17. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
Zuradelli M; Masci G; Biancofiore G; Gullo G; Scorsetti M; Navarria P; Tancioni F; Berlusconi M; Giordano L; Santoro A
Oncologist; 2009 May; 14(5):548-56. PubMed ID: 19411682
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic Acid and renal toxicity: data from French adverse effect reporting database.
Munier A; Gras V; Andrejak M; Bernard N; Jean-Pastor MJ; Gautier S; Biour M; Massy Z
Ann Pharmacother; 2005; 39(7-8):1194-7. PubMed ID: 15956222
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
Berenson JR; Yellin O; Crowley J; Makary A; Gravenor DS; Yang HH; Upadhyaya GH; Flinn IW; Staszewski H; Tiffany NM; Sanani S; Farber CM; Morganstein N; Bolejack V; Nassir Y; Hilger JD; Sefaradi A; Shamouelian A; Swift RA
Am J Hematol; 2011 Jan; 86(1):25-30. PubMed ID: 21120861
[TBL] [Abstract][Full Text] [Related]
20. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
